Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 24
Filter
1.
J Drugs Dermatol ; 23(6): e154-e155, 2024 06 01.
Article in English | MEDLINE | ID: mdl-38834216

ABSTRACT

Sunscreen is an essential component of sun protection. The most important characteristics for patient selection of sunscreens have not been evaluated. A cross-sectional survey study was performed at an academic dermatology office. The sunscreen characteristic chosen most frequently was SPF (75.2%). Fewer patients selected broad-spectrum (20.7%) and water-resistance (22.7%). There remains a gap in patient knowledge regarding AAD recommendations for sunscreen characteristics and educational initiatives may be required. J Drugs Dermatol. 2024;23(6):e154-e155.     doi:10.36849/JDD.8324e  .


Subject(s)
Sunscreening Agents , Humans , Sunscreening Agents/administration & dosage , Cross-Sectional Studies , Female , Male , Adult , Middle Aged , Sun Protection Factor , Health Knowledge, Attitudes, Practice , Surveys and Questionnaires/statistics & numerical data , Aged , Sunburn/prevention & control , Young Adult
2.
J Drugs Dermatol ; 23(8): e171-e172, 2024 08 01.
Article in English | MEDLINE | ID: mdl-39093649

ABSTRACT

Sunscreen greatly reduces the risk of skin cancer and is recommended as a critical component of sun protection. There is limited literature on patient preferences for sunscreen characteristics. A cross-sectional survey was administered to patients in an urban city and rural area in the United States. Sun Protection Factor (SPF) was consistently the most important factor for patients when selecting sunscreen. However, numerous preferences for sunscreen characteristics vary between the 2 regions, including dermatologist recommendation, texture, ingredients, cost, broad-spectrum, and brand. Gaps in patient knowledge of sunscreen recommendations may be present and further educational programs may be necessary. J Drugs Dermatol. 2024;23(8):e171-e172. doi:10.36849/JDD.8449.


Subject(s)
Patient Preference , Rural Population , Skin Neoplasms , Sun Protection Factor , Sunscreening Agents , Urban Population , Humans , Sunscreening Agents/administration & dosage , Cross-Sectional Studies , Rural Population/statistics & numerical data , United States , Female , Urban Population/statistics & numerical data , Male , Middle Aged , Adult , Skin Neoplasms/prevention & control , Skin Neoplasms/epidemiology , Aged , Surveys and Questionnaires/statistics & numerical data , Young Adult , Sunburn/prevention & control , Sunburn/epidemiology , Health Knowledge, Attitudes, Practice
3.
J Drugs Dermatol ; 23(8): 592-599, 2024 Aug 01.
Article in English | MEDLINE | ID: mdl-39093660

ABSTRACT

BACKGROUND: Plaque psoriasis is a chronic, relapsing systemic illness that has a significant effect on quality of life. Bimekizumab is the first monoclonal antibody to target both interleukin (IL)-17A and IL-17F, and recently received Food and Drug Administration (FDA) approval for moderate to severe plaque psoriasis. Guidance is necessary regarding the safety of bimekizumab. METHODS: A comprehensive literature search of PubMed, Scopus, and Google Scholar was completed for English-language original research articles on the safety of bimekizumab for moderate to severe psoriasis. A panel of 9 dermatologists and 1 rheumatologist with significant expertise in the treatment of psoriasis gathered to review the articles and create consensus statements on this new medication. A modified Delphi process was used to approve each statement, and strength of recommendation was assigned using the Strength of Recommendation Taxonomy criteria. RESULTS: The literature search produced 110 articles that met the criteria. A thorough screening of the studies for relevance to the research question resulted in 15 articles. These were distributed to all panelists for review prior to a roundtable discussion. The panel unanimously voted to adopt 5 consensus statements and recommendations, all of which were given a strength of "A". CONCLUSION: Bimekizumab has a safety profile consistent with other biologics, except for a higher risk of oral candidiasis. Its hepatic safety profile is comparable with other currently FDA-approved biologics for plaque psoriasis. In addition, the data do not support an association of bimekizumab with suicide, and the incidence of inflammatory bowel disease is not greater than the incidence of other IL-17 blockers. J Drugs Dermatol. 2024;23(8):592-599. doi:10.36849/JDD.8246.


Subject(s)
Antibodies, Monoclonal, Humanized , Consensus , Interleukin-17 , Psoriasis , Humans , Psoriasis/drug therapy , Psoriasis/diagnosis , Antibodies, Monoclonal, Humanized/adverse effects , Antibodies, Monoclonal, Humanized/administration & dosage , Antibodies, Monoclonal, Humanized/therapeutic use , Interleukin-17/antagonists & inhibitors , Interleukin-17/immunology , Dermatologic Agents/adverse effects , Dermatologic Agents/therapeutic use , Dermatologic Agents/administration & dosage , Delphi Technique , Severity of Illness Index
4.
J Drugs Dermatol ; 23(9): 774-781, 2024 09 01.
Article in English | MEDLINE | ID: mdl-39231082

ABSTRACT

BACKGROUND: Cutaneous melanoma (CM) is associated with a higher mortality rate than most other skin cancers. The purpose of this expert consensus panel was to review the published literature on new technological advancements for the diagnosis and prognosis for CM and provide updated guidance on their usage. METHODS: A comprehensive literature search of PubMed, Scopus, and Google Scholar was completed for English-language original research articles on the topics of non-invasive diagnostic and prognostic testing for CM, including gene expression profiling (GEP) and electrical impedance spectroscopy (EIS). A panel of 10 dermatologists with significant expertise in the treatment of CM gathered to review the articles and create consensus statements. A modified Delphi process was used to approve each statement and a strength of recommendation was assigned using widely recognized Strength of Recommendation Taxonomy criteria. RESULTS: The literature search produced 200 articles that met the criteria. A screening of the studies resulted in 19 articles. These were distributed to all panelists for review prior to a roundtable discussion. The panel unanimously voted to adopt 7 consensus statements and recommendations, 5 of which were given a strength of "A", 1 of which was given a strength of "B," and 1 of which was given a strength of "C". CONCLUSION: The 2-GEP test and EIS can aid in the precise diagnosis of clinically indeterminate lesions and the 23-GEP test can be used when histopathology is equivocal. The 31-GEP test can enhance prognostic assessment beyond AJCC8 staging and improve clinical decision-making. J Drugs Dermatol. 2024;23(9):774-781. doi:10.36849/JDD.8365R1.


Subject(s)
Consensus , Dielectric Spectroscopy , Melanoma , Skin Neoplasms , Humans , Melanoma/diagnosis , Melanoma/genetics , Melanoma/pathology , Skin Neoplasms/diagnosis , Skin Neoplasms/pathology , Skin Neoplasms/genetics , Prognosis , Dielectric Spectroscopy/methods , Gene Expression Profiling , Delphi Technique
5.
Dermatol Surg ; 48(6): 636-641, 2022 06 01.
Article in English | MEDLINE | ID: mdl-35333198

ABSTRACT

BACKGROUND: The COVID-19 pandemic has caused an increasing shift toward the utilization of telehealth services. There are limited data on patient preferences for these services in dermatologic surgery. OBJECTIVE: To evaluate patient preferences regarding telehealth in dermatologic surgery for pre- and postsurgical care. METHODS: A survey was administered to patients in an academic dermatology practice. RESULTS: Two hundred twenty-four patients participated. An in-person presurgical consultation was preferred by 62.1%, and a postsurgical in-person visit was preferred by 67.7%. The most commonly cited reason was desire for physical interaction with their surgeon. For each 10-year increase in age, there was a 1.26-fold and 1.12-fold increase in preference for in-person consultation and follow-up, respectively. Eighty-seven percent felt safe during office visit, and 41% reported no anxiety regarding fear of contracting COVID-19. The proportion of patients preferring in-person pre- or postsurgical visits was similar regardless of sex, presence of an immunocompromising condition, prior dermatologic surgery, anxiety level for contracting COVID-19, and perceived level of office safety. CONCLUSION: A majority of patients prefer in-person visits for pre- and postsurgical care. Older patients have a greater preference for in-person care. Anxiety level regarding COVID-19 and perceived level of office safety were not related to preference for in-person visits.


Subject(s)
COVID-19 , Telemedicine , COVID-19/epidemiology , Dermatologic Surgical Procedures , Humans , Pandemics , Patient Preference
6.
J Am Acad Dermatol ; 84(4): 1023-1029, 2021 Apr.
Article in English | MEDLINE | ID: mdl-33253841

ABSTRACT

BACKGROUND: Information on recent trends in overall and subgroup incidences in psoriasis is limited. OBJECTIVE: To estimate current incidence of psoriasis in the United States, compare incidences among demographic subgroups, and evaluate recent disease trends. METHODS: Retrospective cohort analysis of psoriasis patients identified with electronic health records between 2014 and 2018. RESULTS: Incidence rate in the overall population (n = 2,152,192) was 63.8 (95% confidence interval [CI] 61.8-65.8) per 100,000 person-years. Incidence increased with age and peaked among individuals aged 70 to 79 years (92.3 [95% CI 85.1-100.0] per 100,000 person-years). Incidence was similar between men (62.8 [95% CI 59.8-65.9] per 100,000 person-years) and women (64.8 [95% CI 62.2-67.4] per 100,000 person-years). Standardized incidence rate for Whites (75.3 [95% CI 72.7-78.0] per 100,000 person-years) was greater than that for Hispanic/Latino patients (52.2 [95% CI 44.9-60.3] per 100,000 person-years; P < .001), patients of other race (54.3 [95% CI 46.5-62.9] per 100,000 person-years; P < .001), and Blacks (24.9 [95% CI 21.4-28.8] per 100,000 person-years; P < .001). Incidence appears to be stable within a recent 5-year period. LIMITATIONS: Estimates were derived from approximately 15% of the health care-seeking US population. CONCLUSION: Psoriasis incidence in the United States appears to increase with age, is similar between sexes, and is greatest among Whites.


Subject(s)
Psoriasis/epidemiology , Adolescent , Adult , Age Distribution , Aged , Aged, 80 and over , Electronic Health Records , Ethnicity/statistics & numerical data , Female , Humans , Incidence , Male , Middle Aged , Retrospective Studies , Sex Distribution , United States/epidemiology , Young Adult
7.
J Arthroplasty ; 35(6S): S325-S329, 2020 06.
Article in English | MEDLINE | ID: mdl-32088056

ABSTRACT

BACKGROUND: Urinary bladder catheters are potential sources of infection after total hip arthroplasty (THA). Therefore, the goal of this study was to determine if intermittent catheterization provides a decreased risk of postoperative urinary tract infections (UTIs) compared with indwelling catheterization in THA patients. METHODS: Patients undergoing THA at 15 hospitals within a large health system were prospectively collected between 2017 and 2019 and then stratified based on catheterization technique: no-catheter; indwelling catheter-only; intermittent catheter-only; and both intermittent and indwelling catheter. Patient demographics, medical comorbidities, anesthesia types, and postoperative UTIs were assessed. Independent Student t-tests were used to perform univariate analyses for the catheterization groups. Multiple linear regression models were used to compare the different groups while controlling for confounding variables. RESULTS: There were a total of 7306 THA patients recorded with 5513 (75%) no-catheter, 1181 (16%) indwelling catheter-only, 285 (3.9%) intermittent catheter-only, and 327 (4.5%) indwelling and intermittent catheterization patients. A total of 580 patients experienced postoperative UTI. Urinary bladder catheterization increased the risk of postoperative UTIs (P < .001) in univariate analyses. Multiple linear regression models showed that indwelling catheter-only (OR: 2.178, P < .001), intermittent catheterization (OR: 1.975, P = .003), and both indwelling and intermittent (OR: 2.372, P = .002) were more likely to experience UTIs compared with no catheters. CONCLUSION: This study found that patients treated with indwelling catheterization, with or without preceding intermittent catheterization, were significantly more likely to experience UTIs. Therefore, in an effort to decrease the risk of UTIs, THA patients experiencing postoperative urinary retention should be treated with intermittent catheterization.


Subject(s)
Arthroplasty, Replacement, Hip , Urinary Tract Infections , Arthroplasty, Replacement, Hip/adverse effects , Catheters, Indwelling , Humans , Urinary Bladder , Urinary Catheterization/adverse effects , Urinary Catheters , Urinary Tract Infections/epidemiology , Urinary Tract Infections/etiology , Urinary Tract Infections/prevention & control
12.
World J Surg ; 42(6): 1706-1713, 2018 06.
Article in English | MEDLINE | ID: mdl-29143092

ABSTRACT

BACKGROUND: To determine whether minimally invasive surgery (MIS) training improves outcomes in laparoscopic appendectomy, a procedure that is commonly performed in general surgery training. METHODS: Retrospective review was conducted of all patients undergoing laparoscopic appendectomy for suspected acute appendicitis between 2014 and 2015 at a single-center, tertiary-care academic institution. Patients operated on by MIS-trained surgeons (MIS group) were compared to those operated on by general surgeons (GS group). Single-incision and multiport laparoscopic appendectomies were included; open approach, known malignancy, and interval appendectomies were excluded. RESULTS: A total of 507 patients were included in the study: 181 patients in the MIS group and 326 in the GS group. There were no differences in patient demographics or medical comorbidities between groups and most patients were ASA class 1 or 2. Patients operated on by MIS-trained surgeons had significantly shorter operative time (43 min, IQR 32-60 vs. 58 min, IQR 44-81; p < 0.001) and fewer intra-operative adverse events (0/181 vs. 8/326, 2.5%; p = 0.03). There was no difference in number of postoperative adverse events between groups (6/181, 3.3% vs. 21/326, 6.4%; p = 0.13). In the MIS group, subgroup analysis of single-incision versus multiport appendectomy showed no differences in intra-operative or postoperative adverse events. On multivariable linear regression, lack of MIS training and traditional multiport approach had the greatest effects on prolonging operative time (11.2 and 12.8 min, respectively; p = 0.001). CONCLUSIONS: MIS fellowship improves operative metrics and patient outcomes even in basic laparoscopy.


Subject(s)
Appendectomy/education , Appendectomy/methods , Appendicitis/surgery , Fellowships and Scholarships/standards , Laparoscopy/education , Adolescent , Adult , Aged , Aged, 80 and over , Appendectomy/standards , Clinical Competence , Female , Humans , Laparoscopy/standards , Male , Middle Aged , Minimally Invasive Surgical Procedures/education , Minimally Invasive Surgical Procedures/standards , Retrospective Studies , Treatment Outcome , Young Adult
14.
Curr Pain Headache Rep ; 19(12): 53, 2015 Dec.
Article in English | MEDLINE | ID: mdl-26474783

ABSTRACT

Migraine is a debilitating headache disorder that has a significant impact on the world population, in both economic and sociologic capacities. Migraine has two main categories: (1) chronic migraine (CM), defined as the patient having 15 or more headache days per month, with at least five attacks fulfilling measures for EM with aura or EM without aura, and (2) episodic migraine (EM), defined as less than 15 headache days per month. With this definition, CM can only exist in the presence of EM, and it questions whether the two are separate diseases. Migraine has a significant impact on the population, as each year, about 2.5 % of patients with EM develop new-onset CM (Manack et al., Curr Pain Headache Rep 15:70-78, 2011) (Loder et al. Headache 55:214-228, 2015), with certain risk factors being evident only with CM. In addition, there are comorbid diseases that are only associated with CM, suggesting two separate diseases rather than one. Differentiation in response to treatments, both preventive and abortive, demonstrates both a similarity and a difference in EM versus CM. Also, comparing the two processes based upon functional imaging has been a recent development, beginning to show a physiological difference in regional cortical thickness, cortical surface area, and regional volumes in patients with EM and CM. Evidence regarding whether EM and CM demonstrate one disease with a significant level of complication or if two independent processes is inconclusive, and additional research must be performed to further characterize their relationship.


Subject(s)
Cerebral Cortex/pathology , Migraine Disorders/diagnosis , Chronic Disease , Functional Neuroimaging/methods , Humans , Migraine Disorders/physiopathology , Population Surveillance
15.
Int J Dermatol ; 63(1): 73-78, 2024 Jan.
Article in English | MEDLINE | ID: mdl-38131454

ABSTRACT

BACKGROUND: Artificial intelligence tools such as OpenAI's GPT-4 have shown promise in medical education, but their potential in dermatology remains unexplored. OBJECTIVES: To assess GPT-4's performance on dermatology board-style questions and determine its value as a supplementary educational tool for trainees and educators. METHODS: This cross-sectional study evaluated GPT-4's performance on 250 random dermatology board-style questions sampled from the American Academy of Dermatology's Board Prep Plus resource. Questions were divided into five subspecialties and various difficulty levels. GPT-4 responses were compared to the correct answers and evaluated by two physicians. RESULTS: GPT-4 achieved an overall accuracy of 75% on the 250 questions, with no significant variation based on subspecialty or question difficulty. The most common errors were factual and misunderstanding inaccuracies. Responses scored high in clarity, accuracy, and relevance but frequently lacked depth and completeness. CONCLUSION: GPT-4 performed to a high degree and demonstrated promising performance as an educational adjunct in dermatology. Improvements in response depth and completeness are needed before its use as an unsupervised learning tool is established.


Subject(s)
Artificial Intelligence , Dermatology , Education, Medical , Educational Measurement , Cross-Sectional Studies
16.
JAMA Dermatol ; 160(6): 651-657, 2024 Jun 01.
Article in English | MEDLINE | ID: mdl-38506826

ABSTRACT

Importance: Assessment of type, severity, and impact of dermatologic adverse events (DAEs) necessitates well-developed and validated clinician-reported outcome measures (ClinROMs) and patient-reported outcome measures (PROMs) that evaluate concepts specific to mucocutaneous toxic effects and that allow appropriate interpretation and comparison of DAEs across trials. Objective: To evaluate heterogeneity and quality of ClinROMs and PROMs used to assess DAEs from systemic cancer therapy. Evidence Review: Two systematic reviews were conducted by searching PubMed and Embase databases from inception through March 7, 2023, and April 12, 2023. The first search included randomized clinical trials and observational studies reporting systemic cancer treatment-induced DAEs assessed by a ClinROM or PROM. The second included studies evaluating measurement properties of frequently used ClinROM and PROM instruments. The Consensus-Based Standards for the Selection of Health Measurement Instruments risk of bias tool was used to evaluate methodologic quality of validation assessments. Findings: A total of 395 studies were included. The Common Terminology Criteria for Adverse Events (CTCAE) was utilized in 331 studies meeting inclusion criteria (83.8%). At least 1 skin-related PROM was infrequently utilized in systemic chemotherapy clinical trials (79 studies [20.0%]). Most frequently utilized PROMs were the Dermatology Life Quality Index (DLQI; 34 studies [8.6%]) and Skindex-16 (20 studies [5.1%]). Among studies capturing DAEs, 115 (29.1%) reported a nondescript term (ie, rash) as the only DAE. Eight studies described 44 property assessments of the CTCAE, DLQI, and Skindex. There were no studies evaluating content validity, intrarater reliability, or measurement error for the CTCAE, DLQI, or Skindex. There were no studies evaluating structural validity, internal consistency, and responsiveness of DLQI or Skindex. Interrater reliability and responsiveness were each assessed for 1 DAE-related component of the CTCAE. Construct validity for CTCAE, DLQI, and Skindex was evaluated in 29 (65.9%), 3 (6.8%), and 9 (20.5%) assessments, respectively. Conclusions and Relevance: In this systematic review, there was a narrow spectrum of ClinROMs and PROMs with limited validity for the measurement of DAEs in the context of systemic chemotherapy interventions in clinical trials. Report of trial DAEs often had low morphologic specificity and meaning. Based on existing gaps in measurement and report of DAEs, a frequent and impactful adverse event to chemotherapy, the framework for evaluating cutaneous toxic effects in oncology trials may need collaborative reevaluation.


Subject(s)
Antineoplastic Agents , Neoplasms , Patient Reported Outcome Measures , Humans , Neoplasms/drug therapy , Antineoplastic Agents/adverse effects , Antineoplastic Agents/administration & dosage , Skin Diseases/chemically induced , Skin Diseases/diagnosis , Outcome Assessment, Health Care , Randomized Controlled Trials as Topic
17.
Dermatol Ther (Heidelb) ; 14(2): 323-339, 2024 Feb.
Article in English | MEDLINE | ID: mdl-38340237

ABSTRACT

INTRODUCTION: Psoriasis is a chronic inflammatory condition affecting the skin, joints, and several other organ systems with significant disease burden. Bimekizumab is the first monoclonal antibody targeting both interleukin (IL)-17A and interleukin-17F and has demonstrated efficacy for treating moderate to severe psoriasis. Limited guidelines exist for incorporating this drug into clinical practice. The purpose of this study was for a panel of experts in psoriasis management to synthesize current literature and provide consensus statements with guidance on use of bimekizumab. METHODS: A comprehensive literature search of PubMed, Scopus, and Google Scholar was completed for English-language original research articles on the use of bimekizumab for moderate to severe psoriasis and psoriatic arthritis. A panel of nine dermatologists with significant expertise in treatment of psoriasis gathered to review the articles and create consensus statements on this new medication. A modified Delphi process was used to approve each statement and a strength of recommendation was assigned using Strength of Recommendation Taxonomy criteria. RESULTS: The literature search produced 102 articles that met criteria. A thorough screening of the studies for relevance to the research question resulted in 19 articles. These were distributed to all panelists for review prior to a roundtable discussion. The panel unanimously voted to adopt 14 consensus statements and recommendations, 12 of which were given a strength of "A", one of which was given a strength of "B", and one of which was given a strength of "C". CONCLUSION: Bimekizumab results in rapid and long-lasting clinical improvement for patients with moderate to severe plaque psoriasis and psoriatic arthritis. It has demonstrated superior efficacy when compared to several other biologics. The safety profile is consistent with other biologics, except for an increased incidence of oropharyngeal candidiasis.

18.
Dermatol Clin ; 41(4): 611-617, 2023 Oct.
Article in English | MEDLINE | ID: mdl-37718018

ABSTRACT

The retirement process is an individualized endeavor. Both financial and social aspects are important to consider when making plans for retirement. In this article, we discuss details of retirement planning, including the need to save, how much and when to start saving, and types of retirement plans. We also review key considerations for deciding when to retire as well as aspects of retirement outside of financial planning, such as redefining one's purpose and finding meaningful activities to fill the void of work.


Subject(s)
Retirement , Humans
19.
Arch Dermatol Res ; 315(3): 339-346, 2023 Apr.
Article in English | MEDLINE | ID: mdl-36198917

ABSTRACT

Lichen sclerosus (LS) is a chronic inflammatory skin disease commonly affecting the anogenital area with less frequent extragenital occurrence. Extragenital LS cutaneous manifestations vary and precipitating factors are not well described. Recent evidence for etiology and clinical associations of extragenital LS provide insight into disease recognition and pathogenesis. Novel diagnostic techniques as well as treatment standardization have the potential to improve management of this rare condition. This review details both past and new insights into the pathogenesis, clinical manifestations, and treatment options of extragenital LS.


Subject(s)
Dermatitis , Lichen Sclerosus et Atrophicus , Humans , Lichen Sclerosus et Atrophicus/diagnosis , Lichen Sclerosus et Atrophicus/therapy , Lichen Sclerosus et Atrophicus/complications , Dermatitis/complications , Chronic Disease
20.
Arch Dermatol Res ; 315(7): 2155-2157, 2023 Sep.
Article in English | MEDLINE | ID: mdl-36856857

ABSTRACT

There is limited data on benefits of healing after Mohs surgery using porcine xenografts (PXs) compared to second intention (SI). This case series sought to describe healing time, scar size, cosmetic outcome, pain, and infection rates in patients treated with PX or SI for wounds on lower extremities. 14 patients were enrolled. Six patients received treatment with SI, and eight patients received PX. 11 patients (4 SI, 7 PX) completed follow-up visit after 3 months (79% follow-up rate) when primary outcome measure was assessed. 64% of patients took > 3 months to heal. 72% of patients healed within 6 months post-surgery. Scars contracted by > 50% in 7/11 patients completing follow-up. In SI group, 3/5 patients self-reported pain level > 1 out of 10 at 1-week post-surgery compared to 3/8 in the PX group. Two patients in each group developed post-operative wound infection and three patients in PX group experienced other adverse events. These results suggest that healing with PX or SI resulted in small scar size, low post-operative pain level, and low rate of adverse events. Both groups had longer healing times than expected.


Subject(s)
Cicatrix , Mohs Surgery , Animals , Swine , Humans , Cicatrix/etiology , Cicatrix/pathology , Mohs Surgery/adverse effects , Heterografts , Intention , Lower Extremity/surgery , Lower Extremity/pathology , Pain/etiology
SELECTION OF CITATIONS
SEARCH DETAIL